Italia markets closed
Dow Jones
38.865,53 +13,26 (+0,03%) Nasdaq
16.326,65 -22,59 (-0,14%) Nikkei 225
38.835,10 +599,03 (+1,57%) EUR/USD
1,0754 -0,0020 (-0,18%) Bitcoin EUR
58.719,70 -283,88 (-0,48%) CMC Crypto 200
1.304,05 -61,07 (-4,48%)
Illumina, Inc. (ILMN)
NasdaqGS - NasdaqGS Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
In data: 02:57PM EDT. Mercato aperto.
| Chiusura precedente | 118,98 |
| Aperto | 119,00 |
| Denaro | 113,30 x 100 |
| Lettera | 113,70 x 100 |
| Min-Max giorno | 113,16 - 119,43 |
| Intervallo di 52 settimane | 89,00 - 213,91 |
| Volume | |
| Media Volume | 1.648.414 |
| Capitalizzazione | 18,092B |
| Beta (5 anni mensile) | 1,19 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -8,15 |
| Prossima data utili | 07 ago 2024 - 12 ago 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 150,96 |
GlobeNewswireMyriad Genetics and Illumina Achieve Milestones in Strategic Partnership to Support Biopharma Clinical Trials
Myriad can conduct prospective clinical trials using Illumina’s TruSight Oncology Comprehensive Investigational Use Only testSALT LAKE CITY, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced two key milestones in its strategic partnership with Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, to advance and support clinical research for gene-based, targeted thera
© 2024 Yahoo. Tutti i diritti riservati.